Explore our FDA-approved Shield™ blood-based screening test. Discover how our advanced technology detects cancer early, when it's most treatable.

Explore the SHIELD study, a prospective, observational trial focusing on screening for high frequency malignant diseases.

Guardant Health’s vision is to transform cancer care across all stages of the disease through the power of blood. The continuum of care includes patients with early-stage and advanced …

At Guardant Health, we believe a simple blood test can improve lung cancer screening compliance by overcoming barriers associated with current methods, such as low-dose CT …

2024年7月29日 · PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. Food and Drug …

2024年6月11日 · The Shield test is a qualitative in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant …

2022年5月2日 · PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the availability of Shield™, the …

2024年8月1日 · Shield outperforms two guideline-recommended stool-based tests, fecal immunochemical test (FIT) and the multi-target stool DNA (mtsDNA) test when considering life …

2025年1月23日 · Shield ™ Is Finally Here A More Pleasant Way to Screen for Colon Cancer. You can now screen at any healthcare visit with Shield, the first FDA-approved blood test for colon …

We have developed the first FDA-approved, Medicare-covered blood test to screen for colorectal cancer, the second leading cause of cancer-related death globally, and are continuing to study …